Advertisement
Screener

MARKER THERAPEUTICS, INC. (MRKR) Proceeds from Debt, Net of Issuance Costs

MARKER THERAPEUTICS, INC. Proceeds from Debt, Net of Issuance Costs

MARKER THERAPEUTICS, INC. (MRKR) reported Proceeds from Debt, Net of Issuance Costs of $387.50 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-04-15.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2015-04-15

  • MARKER THERAPEUTICS, INC. proceeds from debt, net of issuance costs for fiscal 2014 was $387.50K, a 0.00% change from fiscal 2013.
  • MARKER THERAPEUTICS, INC. proceeds from debt, net of issuance costs for fiscal 2013 was $387.50K.
Period endProceeds from Debt, Net of Issuance Costs 12 month
2014-12-31$387.50K
10-K · filed 2015-04-15
2013-12-31$387.50K
10-K · filed 2015-04-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66